

CASE 20

A 65-year-old civil servant from Chonburi

Chief complaint:

Edematous, brownish peau d' orange plaque overlying both anterolateral tibias for 6 months.

Present illness:

The patient presented with localized brownish and thickened infiltrative plaques accompanied with edema on both lower legs for 6 month duration. The lesion initially involved both pretibial areas, but then gradually progressed to the lateral aspect of both legs. They were asymptomatic, however developed secondary impetiginization on one occasion. This resolved after treatment with Augmentin 625 mg three times per day for 2 weeks.

Past history:

She has several underlying medical conditions consisting of long standing diabetes mellitus type 2 and hypertension, which lead to chronic renal insufficiency, proven by ultrasound of KUB system. She also has old lacunar infarction, again possibly a macrovascular complication of her diabetes and hypertension.

Physical examination :

Vital signs:	Pulse 60/m regular rhythm, RR 20/min, BP 150/90 mmHg
GA :	An elderly Thai woman, afebrile, alert
HEENT:	mildly pale, no jaundice, no exophthalmos, no ophthalmoplegia, thyroid gland not enlarged
LN:	not palpable anywhere
Heart & Lungs :	normal
Abdomen:	slightly distended , liver is just palpable, spleen is not palpable, shifting dullness is negative
Extremities:	no varicose veins, pitting edema 2+, no tremor
DTR:	2+ all with normal relaxation

Skin: well-demarcated , thick, infiltrative, brownish verrucous plaques with peau d' orange surface, overlying both anterolateral tibias

Nails: no acropachy



Fig. 20.1




Fig. 20.2




Fig. 20.3

Histopathology: S 06-09075

Mild hyperkeratosis and epidermal hyperplasia. Diffuse edema of the entire dermis. Sparse lymphocytic infiltrate and scattered fibroblast in the dermis.

The section was further sent for special staining alcian blue pH 2.5 and toluidine blue. The results are pending.

Laboratory findings:

- CBC: Hb 11.1 g/dl, Hct 33.8 vol%, normochromic normocytic, WBC 4,360 / mm³, Plt 167,000/mm³
- Bl. Chem: BUN 46 mg/dl, Cr 2.9 mg/dl, Serum albumin 33.9 g/dl
- TFT: FT3 1.09 pg/ml (2.57-4.43), FT4 0.81 ng/dl (0.93-1.17), TSH 2.19 uIU/ml (0.27-4.20)
- Microsomal Ab (Anti-TPO): negative
- Antithyroglobulin: 18.25 IU/ml (0-115.0IU/ml) (Compatible central hypothyroidism)

Diagnosis: Pretibial myxedema, Central Hypothyroidism

Presenter: Kumutnart Prabudhanitisarn

Consultant: Penpun Wattanakrai

Discussion

Pretibial myxedema refers to localized thickening of the pretibial area due to accumulation of acid mucopolysaccharides, mainly hyaluronic acid¹. The same process can be demonstrated in the dorsum of hallux, lower abdomen, arms, shoulders, neck and pinna, hence, unusual location can occur². It is an infrequent manifestation of autoimmune thyroiditis, particularly Graves' disease, occurring 1-10% of these patients. Pretibial myxedema is considered one of the triad of Graves' disease, consisting of exophthalmos, acropachy and pretibial myxedema³. However, there are several reports of euthyroid pretibial myxedema and pretibial myxedema associated with other conditions such as chronic stasis

dermatitis and chronic obesity⁴. A recent demographic report of 178 patients with pretibial myxedema revealed that 91% were classified as hyperthyroid, 3.9% hypothyroid, 2.8% euthyroid and 2.2% were initially hypothyroid and subsequently turned to hyperthyroid during follow up⁵.

There are many clinical variants of pretibial myxedema. In a large series, a review of 150 cases, revealed that 58% had non-pitting edema, 21% had plaques, 20% had nodules, 7% had polypoid or elephantatic type lesion. Lesions varied in color from flesh to purple⁶.

The definite etiology of pretibial myxedema is unclear. It was demonstrated that pretibial myxedema patients have increase hyaluronic acid production by cultured fibroblast from pretibial area. Thyroid stimulating hormone (TSH) receptors have been identified in fibroblasts from pretibial and orbital regions of patients with Graves' disease. However, there were no obvious correlation between clinical manifestation and the presence of TSH receptor antibody⁷. Moreover, this certainly does not explain the presence of myxedema in euthyroid and hypothyroid patients. Another study demonstrated that pretibial myxedema patients have circulating immunoglobulin A₂(IgA₂) fibroblast antibody capable of binding to dermal fibroblast cell line⁸.

Histologic finding in pretibial myxedema shows thickened dermis especially in mid and deep dermis with extensive deposit of acid mucopolysaccharide.

Treatment includes observation in mild form⁵. Topical glucocorticoids, with or without occlusive dressing, or intralesional glucocorticoid injection may be useful. Intravenous immunoglobulin, plasmapheresis and surgical therapy have all been tried. New therapy with octreotide, insulin analog (that suppresses TSH receptor like growth factor activity) and gradient pneumatic compression have been used with variable results.^{1,9}

References

1. Georgala S, Katoulis AC, Geogala C, Katololis EC, Hatzilou E, Stavrianeas NG. Pretibial myxedema as the initial manifestation of Graves' disease. *JEADV* 2002;16: 380-3
2. Noppakun N, Bancheun K, Chandraprsert S. Unusual locations of localised myxedema in Graves' disease. *Arch Dermatol* 1986; 122: 85-8.
3. Anderson CK, Miller OFIII. Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves' disease. *J Am Acad Dermatol* 2003; 48: 970-2.
4. Tokuda S, Kawachi S, Murata H, Saida T. Chronic obesity lymphoedematous mucinosis: three cases of pretibial mucinosis in obese patients with pitting edema. *Br J Dermatol* 2006; 154: 157-61.
5. Schwartz KM, Fatourech V, Ahmed F, Pond GR. Dermopathy of Graves' disease (pretibial myxedema): long term out come. *J Clin Endocrinol Metab* 2002; 87: 438-46.
6. Fatourech V, Pajouni M, Fansway AF. Dermopathy of Graves' disease, Review of 150 cases. *Medicine* 1994; 73: 1-7.
7. Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE. TSH receptor transcripting and TSH receptor like immunoreactivity in orbital and pretibial fibroblast of patients with Graves' ophthalmopathy and pretibial myxedema. *Thyroid* 1997; 7: 3-12.
8. Arnold K, Metcalfe R, Weetman AP. Immunoglobulin A class fibroblast antibodies in patients with Graves' disease and pretibial myxedema. *J Clin Endocrinol Metab* 1995; 80: 3430-7.
9. Graham RM, Cox NH. Systemic Disease and the Skin. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. *Rook's Textbook of Dermatology*. 7th ed. Massachusetts: Blackwell, 2004, Vol 3, 59.1-75.

Ramathibodi Hospital

Interhospital Dermatology Conference

Ramathibodi Hospital

Interhospital Dermatology Conference

August 18, 2006